TORONTO, ON / January 16, 2020 / Theralase® Technologies Inc. (“Theralase” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs“) and their associated drug formulations intended to safely and effectively destroy various cancers, is pleased to announce that the Company has won a precedent-setting lawsuit against anonymous internet posters for defamatory comments.
The suit was filed due to false and disparaging statements posted online by anonymous individuals on the www.stockhouse.com bullboard from late 2014 through 2018. The libelous posts were defamatory not only to the Company, but also certain employees, specifically: Roger Dumoulin-White and Kristina Hachey on a personal level. The false and disparaging content of the posts were severe, including untrue allegations of criminal conduct by Mr. Dumoulin-White and Ms. Hachey and as a result denigrated their professional reputations.
The decision of the Ontario Superior Court of Justice sets the precedent that there can be legal repercussions against anonymous internet posters for posting false and disparaging content. In his ruling, the honorable Justice F.L. Myers wrote, “If people want to make hurtful statements about others and then try to hide from the responsibility to prove the truth or other justification for doing so, then as discussed by Goldstein J., their cowardice is reprehensible and, in my view, they should bear costs on a substantial indemnity basis.”
Kristina Hachey, Chief Financial Officer, Theralase commented, “We are delighted that justice has finally been served and that the reputation of the Company, Mr. Dumoulin-White and myself have been vindicated. Theralase, as a clinical stage pharmaceutical company, is now able to turn its full attention to the completion of its pivotal Non-Muscle Invasive Bladder Cancer (“NMIBC“) clinical study, and if proven successful, the commercialization of the Company’s next-generation anti-cancer technology for the benefit of all stakeholders.”